查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年學名藥市場預測：按產品類型、給藥途徑、藥物類別、適應症、應用、配銷通路、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1372006

到 2030 年學名藥市場預測：按產品類型、給藥途徑、藥物類別、適應症、應用、配銷通路、最終用戶和地區進行的全球分析

Generic Drug Market Forecasts to 2030 - Global Analysis By Product Type (Super Generics, Biosimilar Generics and Simple Generic), Route of Administration, Drug Class, Indication, Application, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球學名藥市場規模為 3,968 億美元，預計到 2030 年將達到 6,045 億美元，預測期內年複合成長率為 6.2%。

學名藥是指在活性成分、劑型、規格、給藥方法、品質、安全性、用途等方面與原廠藥或新藥在生物學上等效的藥物。這些藥物旨在具有與品牌藥物相同的治療效果，但通常以較低的價格出售。學名藥的主要目的之一是提供比品牌藥更經濟的處方箋替代品。學名藥有助於降低病患、保險公司和醫療保健系統的醫療費用。

根據IBEF 2021年11月發布的印度製藥業報告，印度是全球最大的學名藥供應國。印度製藥業供應美國40% 的學名藥需求和英國25% 的藥品需求。

醫療保健支出不斷成長

隨著醫療保健成本的增加，成本控制成為人們更加關注的焦點。消費者、付款人和醫療保健專業人員擴大選擇學名藥，因為它們通常比品牌藥便宜。對平價藥品的需求不斷增加，這對學名藥業務有利。醫療保健行業的成長，例如住院和門診就診的增加以及處方藥使用的增加，通常是醫療費用增加的結果。此外，學名藥的使用有可能顯著降低醫療保健系統的成本，特別是公共資助的計劃，例如醫療補助和醫療保險。這些計劃允許您提供關鍵藥物，同時透過選擇學名藥來更好地管理您的財務，從而幫助推動市場成長。

嚴格法規

限制學名藥成長的主要因素之一是 FDA 對評估學名藥中使用的準確性、副作用和其他成分的嚴格法規。如果製造商不遵守法規標準，藥品經常會被召回。純度、效價、穩定性和藥物釋放是影響學名藥性能的主要因素。為了達到所需的藥物質量，必須將其法規在適當的限度、範圍或分佈內。要求批准學名藥的嚴格政府法規預計將阻礙市場開拓。

專利到期

一旦品牌藥的專利到期，學名藥製造商就可以開始生產和銷售該藥物的仿製品。市場競爭的加劇可能為客戶和醫療保健系統節省成本。在學名藥的幫助下，患者可以以更實惠的價格接受重要的治療。這對於買不起品牌藥的人來說至關重要，而學名藥的供應可以擴大某些藥物的市場。隨著以前買不起品牌藥物的患者開始尋求治療，市場規模可能會擴大。

複雜的學名藥開發

複雜的學名藥開發需要創建更複雜和困難的治療方法的學名藥，包括生物製藥和複雜的配方，這可能對學名藥行業產生許多有害影響。複雜的學名藥開發和核准，特別是生物學名藥（生物製藥的學名藥），可能是一個耗時且資源密集的過程。這延遲了學名藥進入市場的時間，使患者在很長一段時間內沒有負擔得起的選擇。由於證明與參考生物製藥等效性和相似性的嚴格標準阻礙了市場成長，可能會出現法規障礙和延誤。

COVID-19 的影響

與大型製藥部門一樣，學名藥行業也因封鎖、旅行限制以及活性原料藥和成品的製造問題而遭受供應鏈中斷。國際貿易限制影響了仿製原料藥的供應，因為許多活性藥物成分是從中國和印度等國家獲得的。由於大流行，對多種藥品的需求增加，包括抗生素、COVID-19 治療和抗病毒治療。為了滿足不斷成長的醫療保健需求，學名藥製造商必須跟上不斷增加的訂單。

超級學名藥細分市場預計在預測期內規模最大

超級學名藥，也稱為“增強學名藥”或“下一代學名藥”，是比傳統學名藥更有效的最新學名藥。潛在的好處包括提高功效、安全性和便利性。開發超學名藥是為了減輕傳統學名藥的缺點，同時實現合理的價格。與傳統學名藥相比，超學名藥在提高療效和安全性方面具有優勢，這正在推動市場成長。

注射劑領域預計在預測期內年複合成長率最高

預計注射劑領域在預測期內的年複合成長率最高。這是因為注射劑是透過注射輸送的，並且通常直接給藥到循環系統或特定組織中。這些藥物在醫院、診所和居家醫療等各種醫療機構中必不可少，用於治療多種疾病。有多種藥物作為通用注射藥物出售，包括抗生素、止痛藥、荷爾蒙和疫苗。感染疾病、慢性病和重症監護環境只是學名藥用於治療和控制的一些問題。與名牌注射藥物相比，可以顯著節省成本，降低成本並改善獲得醫療保健的機會。

比最大的地區

在亞太地區，中國、印度等國的貢獻最大。根據國際人口科學研究所（IIPS）的研究，截至2021年1月，估計約有7,500萬60歲以上的人患有慢性疾病患者。心血管疾病、高血壓和糖尿病影響全世界約 2000 萬人。因此，印度慢性病盛行率的不斷上升將增加對負擔得起的治療方法的需求，並推動市場的發展。由於上述原因，亞太地區預計成長更快。

複合年複合成長率最高的地區：

歐洲的年複合成長率預計將在預測期內最高。這是由於人口高齡化、控制醫療保健系統成本以及品牌藥物專利到期等原因造成的。在歐盟 (EU)，學名藥的法規受到歐洲藥品管理局 (EMA) 的強烈影響。學名藥要獲得核准，必須滿足嚴格的品質、安全性和功效要求。法律規範使學名藥成為品牌藥物的安全有效的替代品。對生物相似藥（生物製藥的學名藥）的重視、非處方藥 (OTC) 學名藥行業的成長以及數位健康技術對藥物的影響是歐洲學名藥行業的顯著發展。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭關係

第5章 全球學名藥市場：依產品類型

  • 超級通用
  • 生物相似藥
  • 簡單通用

第6章 全球學名藥市場：依給藥途徑分類

  • 可注射的
  • 局部的
  • 口服
  • 舌下
  • 其他給藥途徑

第7章 全球學名藥市場：依藥物類別

  • 止痛藥
  • 退燒劑
  • 抗組織胺藥
  • 抗高血壓
  • 抗生素
  • 抗糖尿病藥
  • 其他藥物類別

第8章 全球學名藥市場：依適應症分類

  • 消化內科
  • 呼吸系統醫療設備
  • 糖尿病學
  • 心臟病學
  • 皮膚科
  • 腫瘤學
  • 其他適應症

第9章 全球學名藥市場：依應用分類

  • 感染疾病
  • 心血管疾病
  • 糖尿病
  • 癌症
  • 胃病
  • 肌肉骨骼疾病
  • 其他用途

第10章 全球學名藥市場：依配銷通路

  • 醫院藥房
  • 線上提供者
  • 零售藥房
  • 其他配銷通路

第11章全球學名藥市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 多專科診所
  • 居家照護
  • 其他最終用戶

第12章全球學名藥市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第13章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第14章公司簡介

  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.,
  • Novartis AG
  • Mylan NV
  • Teva Pharmaceuticals Industries Ltd.
  • Endo International plc
  • Lupin
  • Aurobindo Pharma
  • Hikma Pharmaceuticals PLC
  • STADA Arzneimittel AG
  • Eli Lilly and Company
  • Aspen Holdings
  • Fresenius SE & Co. KGaA.
  • GlaxoSmithKline plc
  • Viatris Inc
  • Amneal Pharmaceuticals, Inc
  • Cipla Ltd
  • Abbott Laboratories
  • Sanofi
  • Baxter International Inc.
  • AbbVie Inc.
Product Code: SMRC24062

According to Stratistics MRC, the Global Generic Drug Market is accounted for $396.8 billion in 2023 and is expected to reach $604.5 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Generic medications are pharmaceuticals that, in terms of their active components, dosage form, strength, mode of administration, quality, safety, and intended use, are bioequivalent to name-brand or innovator medications. They are made to have the same therapeutic effect as the original brand-name medicine, but they are often marketed for less money. Offering more economical substitutes for name-brand prescriptions is one of the main goals of generic medications. They aid in lowering medical expenses for patients, insurers, and healthcare systems.

According to the Indian Pharmaceutical Industry Report published in November 2021 by IBEF, India is the world's top supplier of generic pharmaceuticals. The Indian pharmaceutical industry supplies 40% of the generic demand in the United States and 25% of all pharmaceuticals in the United Kingdom.

Market Dynamics:

Driver:

Growing healthcare expenditure

Cost containment is given more attention when healthcare expenses grow. For consumers, insurers, and healthcare professionals, generic medications are increasingly chosen since they are often less expensive than name-brand medications. The desire for affordable medicines has grown, which is good for the generic drug business. The growth of the healthcare industry, including more hospital admissions, outpatient visits, and prescription drug use, is frequently a result of growing healthcare costs. Moreover the usage of generic medications may significantly reduce the cost of healthcare systems, especially publicly financed programs like Medicaid and Medicare. These programs can supply vital pharmaceuticals while better controlling their finances by selecting generic substitutes thus propelling the growth of the market.

Restraint:

Strict regulations

One of the key factors restricting the growth of generic medications is the strict restrictions, as the FDA evaluates the accuracy, adverse effects, and other ingredients used in generic pharmaceuticals. If the manufacturers don't adhere to regulatory criteria, pharmaceutical medications are frequently recalled. Purity, potency, stability, and drug release are the main factors that affect how well generic medications perform. To achieve the desired medication quality, they should be regulated within a suitable limit, range, or distribution. The tight government regulations that need clearance for generic medications are anticipated to obstruct market development.

Opportunity:

Patent expirations

When a brand-name medicine's patent runs out, generic drug producers can start creating and selling their copies of the drug. Due to increased market competition, customers and healthcare systems may be able to save money. Patients can acquire vital treatments more affordably with the help of generic pharmaceuticals. This is crucial for people who would not have been able to purchase the brand-name medication and the availability of generic treatments may increase the market for some pharmaceuticals. Patients who previously couldn't afford the name-brand medication may now seek therapy, expanding the market's total size

Threat:

Complex generic development

Complex generic development, which entails creating generic copies of more complex and difficult treatments including biologics and complex formulations, can have a number of detrimental implications on the generic drug industry. Complex generic drug development and approval, especially for biosimilars (generic analogues of biologic drugs), may be a time-consuming and resource-intensive procedure. This additional timeframe delays their arrival into the market, thereby depriving patients of affordable options for an extended period of time. Regulation barriers and delays may result from the demanding criteria for proving bioequivalence and resemblance to the reference biologic which impedes the growth of the market.

COVID-19 Impact

Due to lockdowns, travel restrictions, and issues with the manufacture of active pharmaceutical ingredients (APIs) and completed goods, the generic medicine sector, like the larger pharmaceutical industry, experienced supply chain disruptions. Restrictions on international commerce had an impact on the availability of generic medications because many APIs are obtained from nations like China and India. Demand for several medicines, including as antibiotics, COVID-19 treatment pharmaceuticals, and antiviral treatments, increased as a result of the pandemic. To address the expanding demand for healthcare, generic medicine makers have to react to growing orders.

The super generics segment is expected to be the largest during the forecast period

The super generics segment is estimated to have a lucrative growth, because the super generics, sometimes known as "enhanced generics" or "next-generation generics," are a modern subset of generic medications that attempt to provide certain benefits above more conventional generics. Improved effectiveness, safety, and convenience are possible benefits. Super generics are created to alleviate some of the drawbacks of traditional generics while still being reasonably priced. When compared to conventional generic versions, super generics may have advantages in terms of improved therapeutic effectiveness and safety profiles which drives the market growth.

The injectable segment is expected to have the highest CAGR during the forecast period

The injectable segment is anticipated to witness the highest CAGR growth during the forecast period, as these are provided through injection, often into the circulation or directly into particular tissues. These medications are essential in a variety of healthcare settings, such as hospitals, clinics, and home care and they are used to treat a wide spectrum of medical disorders. A wide variety of drugs, including antibiotics, analgesics, hormones, vaccinations, and more, are available as injectable generics. Infections, chronic illnesses, and critical care scenarios are just a few of the problems they are used to treat and control. When compared to name-brand injectable medications, they can provide considerable cost savings, lowering the cost and increasing accessibility to healthcare.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to rising medical knowledge among the populace and the region's aging demographic; In the Asia-Pacific area, countries like China and India contribute more than other countries do. A research by the International Institute for Population Sciences (IIPS) estimates that in January 2021, there were around 75 million chronically unwell Indians over the age of 60. Cardiovascular disease, hypertension, and diabetes affect roughly 20 million individuals worldwide. Thus, the increased incidence of chronic illnesses in the nation would increase the need for affordable therapies, propelling the market under study. As a result of the aforementioned reasons, the Asia-Pacific region is anticipated to have quicker growth.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to reasons including aging populations, healthcare systems' efforts to control costs, and the expiration of brand-name pharmaceuticals' patents. In the European Union, generic medicine regulation is heavily influenced by the European Medicines Agency (EMA). To be approved, generic medications must adhere to strict quality, safety, and effectiveness requirements. Generic medications are safe and effective substitutes for their brand-name equivalents thanks to the regulatory framework. The emphasis on biosimilars (generic copies of biologic pharmaceuticals), the growth of the over-the-counter (OTC) generic drug industry, and the influence of digital health technology on medication are a few prominent developments in the European generic drug business.

Key players in the market:

Some of the key players profiled in the Generic Drug Market include: Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Mylan NV, Teva Pharmaceuticals Industries Ltd., Endo International plc, Lupin, Aurobindo Pharma, Hikma Pharmaceuticals PLC, STADA Arzneimittel AG, Eli Lilly and Company, Aspen Holdings, Fresenius SE & Co. KGaA., GlaxoSmithKline plc, Viatris Inc, Amneal Pharmaceuticals, Inc, Cipla Ltd, Abbott Laboratories, Sanofi, Baxter International Inc. and AbbVie Inc.

Key Developments:

In October 2023, Pfizer presents new data at IDWeek 2023 Highlighting advances in prevention and treatment of certain respiratory illnesses and Other Infectious Diseases. Presentations showcase diversity and momentum of Pfizer's growing portfolio of vaccines and anti-infectives

In October 2023, Novartis presents new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer. Key data from the Phase III PSMAfore trial has been selected for a Presidential session.

In October 2023, Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment. Collaboration leverages the innovative R&D and commercial expertise of both companies.

In September 2023, Teva Presents Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023.

Product Types Covered:

  • Super Generics
  • Biosimilar Generics
  • Simple Generic

Route of Administrations Covered:

  • Injectable
  • Topical
  • Oral
  • Sublingual
  • Other Routes of Administrations

Drug Classes Covered:

  • Analgesics
  • Antipyretic
  • Antihistamines
  • Antihypertensive
  • Antibiotics
  • Antidiabetic
  • Other Drug Classes

Indications Covered:

  • Gastroenterology
  • Pulmonology
  • Diabetology
  • Cardiology
  • Dermatology
  • Oncology
  • Other Indications

Applications Covered:

  • Infectious Diseases
  • Cardiovascular Diseases
  • Diabetes
  • Cancer
  • Gastric Diseases
  • Musculoskeletal Diseases
  • Other Applications

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Providers
  • Retail Pharmacies
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Multi-Specialty Clinics
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Generic Drug Market, By Product Type

  • 5.1 Introduction
  • 5.2 Super Generics
  • 5.3 Biosimilar Generics
  • 5.4 Simple Generic

6 Global Generic Drug Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Injectable
  • 6.3 Topical
  • 6.4 Oral
  • 6.5 Sublingual
  • 6.6 Other Routes of Administrations

7 Global Generic Drug Market, By Drug Class

  • 7.1 Introduction
  • 7.2 Analgesics
  • 7.3 Antipyretic
  • 7.4 Antihistamines
  • 7.5 Antihypertensive
  • 7.6 Antibiotics
  • 7.7 Antidiabetic
  • 7.8 Other Drug Classes

8 Global Generic Drug Market, By Indication

  • 8.1 Introduction
  • 8.2 Gastroenterology
  • 8.3 Pulmonology
  • 8.4 Diabetology
  • 8.5 Cardiology
  • 8.6 Dermatology
  • 8.7 Oncology
  • 8.8 Other Indications

9 Global Generic Drug Market, By Application

  • 9.1 Introduction
  • 9.2 Infectious Diseases
  • 9.3 Cardiovascular Diseases
  • 9.4 Diabetes
  • 9.5 Cancer
  • 9.6 Gastric Diseases
  • 9.7 Musculoskeletal Diseases
  • 9.8 Other Applications

10 Global Generic Drug Market, By Distribution Channel

  • 10.1 Introduction
  • 10.2 Hospital Pharmacies
  • 10.3 Online Providers
  • 10.4 Retail Pharmacies
  • 10.5 Other Distribution Channels

11 Global Generic Drug Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals
  • 11.3 Specialty Clinics
  • 11.4 Multi-Specialty Clinics
  • 11.5 Homecare
  • 11.6 Other End Users

12 Global Generic Drug Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Pfizer Inc.
  • 14.2 Sun Pharmaceutical Industries Ltd.,
  • 14.3 Novartis AG
  • 14.4 Mylan NV
  • 14.5 Teva Pharmaceuticals Industries Ltd.
  • 14.6 Endo International plc
  • 14.7 Lupin
  • 14.8 Aurobindo Pharma
  • 14.9 Hikma Pharmaceuticals PLC
  • 14.10 STADA Arzneimittel AG
  • 14.11 Eli Lilly and Company
  • 14.12 Aspen Holdings
  • 14.13 Fresenius SE & Co. KGaA.
  • 14.14 GlaxoSmithKline plc
  • 14.15 Viatris Inc
  • 14.16 Amneal Pharmaceuticals, Inc
  • 14.17 Cipla Ltd
  • 14.18 Abbott Laboratories
  • 14.19 Sanofi
  • 14.20 Baxter International Inc.
  • 14.21 AbbVie Inc.

List of Tables

  • Table 1 Global Generic Drug Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Generic Drug Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Generic Drug Market Outlook, By Super Generics (2021-2030) ($MN)
  • Table 4 Global Generic Drug Market Outlook, By Biosimilar Generics (2021-2030) ($MN)
  • Table 5 Global Generic Drug Market Outlook, By Simple Generic (2021-2030) ($MN)
  • Table 6 Global Generic Drug Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 7 Global Generic Drug Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 8 Global Generic Drug Market Outlook, By Topical (2021-2030) ($MN)
  • Table 9 Global Generic Drug Market Outlook, By Oral (2021-2030) ($MN)
  • Table 10 Global Generic Drug Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 11 Global Generic Drug Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 12 Global Generic Drug Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 13 Global Generic Drug Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 14 Global Generic Drug Market Outlook, By Antipyretic (2021-2030) ($MN)
  • Table 15 Global Generic Drug Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 16 Global Generic Drug Market Outlook, By Antihypertensive (2021-2030) ($MN)
  • Table 17 Global Generic Drug Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 18 Global Generic Drug Market Outlook, By Antidiabetic (2021-2030) ($MN)
  • Table 19 Global Generic Drug Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 20 Global Generic Drug Market Outlook, By Indication (2021-2030) ($MN)
  • Table 21 Global Generic Drug Market Outlook, By Gastroenterology (2021-2030) ($MN)
  • Table 22 Global Generic Drug Market Outlook, By Pulmonology (2021-2030) ($MN)
  • Table 23 Global Generic Drug Market Outlook, By Diabetology (2021-2030) ($MN)
  • Table 24 Global Generic Drug Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 25 Global Generic Drug Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 26 Global Generic Drug Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 27 Global Generic Drug Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 28 Global Generic Drug Market Outlook, By Application (2021-2030) ($MN)
  • Table 29 Global Generic Drug Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 30 Global Generic Drug Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 31 Global Generic Drug Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 32 Global Generic Drug Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 33 Global Generic Drug Market Outlook, By Gastric Diseases (2021-2030) ($MN)
  • Table 34 Global Generic Drug Market Outlook, By Musculoskeletal Diseases (2021-2030) ($MN)
  • Table 35 Global Generic Drug Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 36 Global Generic Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 37 Global Generic Drug Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 38 Global Generic Drug Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 39 Global Generic Drug Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 40 Global Generic Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 41 Global Generic Drug Market Outlook, By End User (2021-2030) ($MN)
  • Table 42 Global Generic Drug Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 43 Global Generic Drug Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 44 Global Generic Drug Market Outlook, By Multi-Specialty Clinics (2021-2030) ($MN)
  • Table 45 Global Generic Drug Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 46 Global Generic Drug Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above